Business Wire

Corindus, A Siemens Healthineers Company, Announces Study Results Demonstrating Safety and Effectiveness of CorPath® GRX Neurovascular System

Share

Corindus, A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System. The data represents a milestone in the company’s commitment to extending precision robotics into neurovascular treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907006221/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CorPath GRX Neurovascular System (Photo: Business Wire)

The prospective, single-arm, international, multi-center, non-inferiority study is the world’s first trial on robotic-assisted neurovascular aneurysm embolization. Principal Investigator Michel Piotin, MD, PhD, Head of the Interventional Neuroradiology Department at the Rothschild Foundation Hospital in Paris, presented the results as part of the AI & New Innovations session at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Nice, France. Key findings of the study showed:

  • The CorPath GRX Neurovascular System demonstrated 94 percent technical success. It achieved the primary effectiveness goal, which was defined as successful completion of the robotic-assisted endovascular procedure absent of any unplanned conversion to a manual procedure.
  • The CorPath GRX Neurovascular System demonstrated 95.7 percent clinical success. It achieved the primary safety goal, defined as patients treated without intra- and periprocedural adverse events, including target aneurysmal rupture, vessel perforation or dissection, and thromboembolic event with neurological decline within 24 hours post-procedure or hospital discharge, whichever occurred first.
  • 64.5 percent of subjects achieved Class I status, meaning complete obliteration of the aneurysm, on the Raymond-Roy Occlusion Classification (RROC), the standard for evaluating aneurysm occlusion.
  • 78.2 percent of subjects showed no clinical symptoms post-procedure, achieving a 0 on the Modified Rankin Scale (mRS) for Neurologic Disability. The remaining 21.8 percent of subjects had an mRS of 1 or 2.

“Neurovascular intervention demands extreme precision to achieve optimal clinical outcomes,” said Dr. Piotin. “The results of the study show the CorPath GRX System helps physicians move efficiently within tortuous and unstable vessels. I am honored to have participated in a groundbreaking study that may lead to an entirely new treatment paradigm in neurovascular care.”

The study included 117 patients from 10 clinical sites in six different countries. It also included a wide range of aneurysms, representing a diverse collection of cases with different locations, sizes and morphology characteristics. The healthcare facilities that treated the trial participants will follow them for 180 days to monitor extended, long-term outcomes.

“The work of our clinical partners on this study marks an early step toward truly transformative change in neurovascular intervention,” said Dr. Raymond Turner, Chief Medical Officer, Neuroendovascular at Corindus. “By incorporating robotic platforms in this space, we are paving the way for remote interventional procedures in the future that will connect patients to specialized interventionalists for treatment, regardless of location. Validating clinical evidence, such as this study, will serve as the foundation for that transformation.”

The CorPath GRX System is the first FDA-cleared and CE Marked medical device for percutaneous coronary and vascular procedures. It earned CE Mark for neurovascular procedures, and healthcare facilities outside of the U.S. currently utilize the platform for neurovascular interventions. The company is currently pursuing additional regulatory clearances for the neurovascular indication.

To learn more about CorPath GRX, please visit www.corindus.com.

ABOUT CORINDUS

Corindus, A Siemens Healthineers Company, is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is a medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Matter Health for Corindus
Jill Gross
+1 978-518-4258
corindus@matternow.com

Siemens Healthineers, North America
Jeffrey Bell
+1 484-868-8346
Jeffrey.t.bell@siemens-healthineers.com

Siemens Healthineers, Europe
Kathrin Palder
+49 173-3645319
kathrin.palder@siemens-healthineers.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Versace Chooses Board to Transform Retail Planning29.9.2022 12:22:00 CEST | Press release

Board, the leading global provider of Intelligent Planning Solutions which help organizations plan smarter — enabling actionable insights and better outcomes, today announced that Versace, the Italian fashion house that symbolizes luxury worldwide, has chosen Board to transform its Retail Planning. The Versace Group distributes its products through a direct network of over 200 owned boutiques and 1,500 distributors worldwide, with a turnover of more than one billion euros. Due to evolving challenges of global sourcing and the change in consumer purchasing habits, Versace recently revamped its retail strategy by opening new stores, strengthening their multi-channel approach and increasing investments in the efficiency of crucial business planning processes. "Board’s Intelligent Planning platform, provides the flexible and easy to use solutions necessary to support the innovation and growth of our brand,” said Francesco Loporcaro, IT Manager at Versace “Our selection of Board was influen

Satellogic Signs Three-Year Agreement with Government of Albania to Access Dedicated Satellite Constellation29.9.2022 12:00:00 CEST | Press release

Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution Earth Observation (“EO”) data collection, announced today that it has reached a three-year agreement with the Government of Albania to develop a Dedicated Satellite Constellation. This unique program derives from Satellogic’s Constellation-as-a-Service model and will provide Albania with responsive satellite imagery capabilities across its sovereign territory. Satellogic’s unique offering enables municipal, state, and national governments to manage a fleet of satellites over a specific area of interest and develop an EO imaging program at unmatched frequency, resolution, and cost. Satellogic will enable ​​Albania to address pressing issues involving agriculture management, illegal crops, illegal construction activity, traffic management, wildfire monitoring, border security, and environmental monitoring through high-quality imagery with country-wide capacity at a cost-effective price point. Albania will have priority acce

Burjeel Holdings Lights Up Burj Khalifa With New Campaign Featuring Shah Rukh Khan29.9.2022 11:27:00 CEST | Press release

A month ahead of his birthday, Indian actor Shah Rukh Khan lit up the world’s tallest building, The Burj Khalifa, on Wednesday evening, in a brand campaign for the UAE-based conglomerate Burjeel Holdings. For the past few years, on Shah Rukh Khan’s birthday, the Burj Khalifa has lit up in honor of the superstar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005378/en/ The brand campaign of Burjeel Holdings featuring Shah Rukh Khan premiering at Burj Khalifa on Wednesday evening (Photo: AETOSWire) Shah Rukh Khan is the face of the group that owns 39 hospitals and medical centers under the Burjeel, Medeor, LLH, Lifecare, and Tajmeel brands in the UAE and Oman. The campaign, ‘We Are Committed To Your Care’, which is set to appear region-wide on multiple platforms features the Abu Dhabi-headquartered healthcare powerhouse’s homegrown success story. It is based on the group’s vision of connecting care, scale & community in

'California Condor' Pays Tribute to Departed Bandmates in New Video29.9.2022 10:30:00 CEST | Press release

Up-and-coming rock band “California Condor” has just released a new music video dedicated to two former bandmates who lost their lives prematurely. Produced to accompany their latest track, “The Band,” the video pays tribute to Ken Loosaar and Johannes Kuslap, who both recently passed away at the ages of 28 and 27 respectively. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005351/en/ ‘California Condor’ Pays Tribute to Departed Bandmates in New Video (Graphic: Business Wire) According to the statement from California Condor, “When California Condor first started out, Ken and Johannes helped the band find its footing. For this, we’ll never forget them. The new video is our way of paying respect – and bidding farewell – to these two highly talented musicians.” In Memorium Originally from the Northern European country of Estonia, California Condor has made a name for itself with its unconventional fusion of various music

Ultivue and ngTMA ® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research29.9.2022 10:00:00 CEST | Press release

Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies and, the Translational Research Unit (TRU) platform of University of Bern, that develops novel workflows for tissue microarray (ngTMA®) construction, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and the use of next generation TMAs to unlock spatial analysis in scientific research and improve the quality of TMAs integrated in clinical and translational research. Ultivue develops unique solutions for use in mIF applications, imaging, and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology. ngTMA® supports research collaborator